Medication-Assisted Treatment (MAT) in Inpatient Opiate Rehab

Medication-assisted treatment (MAT) in inpatient rehab uses FDA-approved medications — buprenorphine, naltrexone, or (rarely inpatient) methadone — alongside behavioral therapy. Unlike outpatient MAT programs, inpatient MAT provides 24-hour medical supervision, which is particularly important during opioid withdrawal when medical complications can occur.

What MAT in Inpatient Rehab Actually Involves

Medication-assisted treatment is one of the most evidence-supported interventions in modern addiction medicine. Multiple decades of research — including NIDA-funded trials, large observational cohorts, and systematic reviews — show that MAT reduces opioid overdose death by approximately half, improves treatment retention, and reduces illicit opioid use compared with behavioral therapy alone. The FDA has approved three medications for opioid use disorder: buprenorphine (often combined with naloxone as Suboxone), naltrexone (oral and extended-release Vivitrol), and methadone.

In an inpatient setting, MAT is one component of an integrated program. The patient is assessed, withdrawal is managed, a medication is selected and titrated, behavioral therapy is delivered alongside medication, and discharge planning coordinates continuation of the medication in the community or at a step-down level of care. The medication is not the program — the program is a structured combination of medical, behavioral, and social interventions, with MAT as one tool.

Inpatient MAT vs outpatient MAT — a critical distinction

Inpatient MAT and outpatient MAT are distinct models of care and are not interchangeable. Inpatient MAT is delivered inside a licensed residential program. The patient lives at the facility, receives medication directly from nursing staff, is medically monitored 24 hours per day, and participates in 30–40 hours per week of structured clinical programming. The environment is controlled and access to substances is restricted.

Outpatient MAT is delivered in office-based practice or in program-based settings where the patient lives at home and visits for medication and, in some cases, counseling. Outpatient MAT has a legitimate role in the care continuum — particularly as a step-down after inpatient completion or as a standalone option for patients with mild-to-moderate severity and stable home environments. But outpatient MAT is not an equivalent substitute for inpatient care during active withdrawal, for severe dependence, or when the home environment will return the patient to use. For moderate-to-severe opioid use disorder, inpatient is the appropriate initial level of care, with outpatient MAT used as step-down continuation.

The Three FDA-Approved Medications Used in MAT

All three FDA-approved medications for opioid use disorder work pharmacologically on the mu-opioid receptor but produce very different clinical effects. Inpatient programs select among them based on the patient's history, severity, and clinical goals.

Buprenorphine (Suboxone) — how it works inpatient

Buprenorphine is a partial opioid agonist. It binds to the mu-opioid receptor with high affinity but only partially activates it — enough to relieve withdrawal and craving without producing the strong euphoric effect of full agonists such as heroin or fentanyl. It has a ceiling effect that reduces overdose risk compared with full agonists. Most inpatient programs induct buprenorphine on day 1 or 2 of detox once the patient is in moderate withdrawal (COWS ≥11–13), titrate to a stable dose over several days, and continue the medication through the residential phase. Long-acting depot injectable buprenorphine (Sublocade) is increasingly used for discharge continuation — a monthly injection that removes the daily adherence burden.

Naltrexone (Vivitrol) — when it's used and why

Naltrexone is an opioid antagonist — it blocks the mu-opioid receptor without activating it. A patient taking naltrexone cannot experience opioid intoxication even if they relapse. Unlike buprenorphine, naltrexone requires complete detoxification before induction; starting it in a patient with residual opioids in circulation produces precipitated withdrawal. Extended-release Vivitrol (monthly intramuscular injection) is commonly initiated toward the end of the inpatient stay once the patient has completed detox and is abstinent. It is particularly appropriate for patients who want a medication without agonist properties and for certain occupational contexts where buprenorphine is not permitted.

Methadone — why it's rarely used in inpatient (vs OTPs)

Methadone is a long-acting full opioid agonist that effectively treats opioid use disorder and reduces overdose mortality at rates comparable to buprenorphine. However, federal law (21 CFR Part 8) restricts methadone for opioid use disorder to federally certified Opioid Treatment Programs — specialized programs licensed specifically to dispense methadone under supervised conditions. Residential rehab facilities are not licensed as OTPs. Inpatient use of methadone is therefore limited: short courses during detox to manage acute withdrawal (particularly for fentanyl patients where buprenorphine induction is challenging), or continuation of existing methadone maintenance for patients already enrolled in an OTP before admission. Patients who need long-term methadone maintenance are typically stepped down from inpatient into an OTP at discharge.

Why MAT Is Controversial — Addressed Honestly

MAT generates more debate than almost any other addiction treatment. The debate is not purely medical — it touches on recovery philosophy, identity, abstinence-based treatment traditions, and personal autonomy. Competitor pages typically defend MAT without acknowledging the criticism. Because this site has no medication or facility product to promote, it can address the controversy directly.

The "trading one drug for another" argument and what evidence says

The most common critique of MAT is that it substitutes one opioid dependency (heroin, fentanyl, oxycodone) for another (buprenorphine, methadone). Framed as a pharmacology question, the critique has a kernel of truth: buprenorphine and methadone are opioids, and patients who take them are physiologically dependent. Discontinuation produces withdrawal. Framed as a clinical outcomes question, the critique misses the point. The medications differ from street opioids in three clinically meaningful ways: (1) they do not produce the rapid intoxication-craving cycle that drives use of heroin and fentanyl; (2) they are dosed once daily (buprenorphine) or monthly (depot formulations) rather than multiple times per day; and (3) they are pharmaceutically pure, dosed by a clinician, and not contaminated with fentanyl or other adulterants.

The empirical outcomes are unambiguous. Multiple large cohort studies and systematic reviews show MAT reduces all-cause mortality by approximately 50% compared with abstinence-based treatment alone. The most recent Cochrane review of buprenorphine found strong evidence of reduced mortality, reduced illicit opioid use, and improved treatment retention. When the outcome measure is "patient alive and not using illicit opioids," MAT outperforms abstinence-only care in the literature.

Why the medical consensus supports MAT

Every major addiction medicine organization — the American Society of Addiction Medicine, the National Institute on Drug Abuse, the Substance Abuse and Mental Health Services Administration, the World Health Organization, and the American Medical Association — classifies MAT as a standard of care for moderate-to-severe opioid use disorder. The consensus is not rhetorical; it follows from the outcomes data above. Patients on MAT die less often, relapse less often, and retain treatment longer than patients who attempt abstinence-only care. In the fentanyl-dominated 2025 overdose environment, this mortality reduction is not a marginal improvement — it is the single largest survivorship factor in the field.

Legitimate concerns about long-term MAT without counseling

Not every concern about MAT is misinformed. A legitimate clinical worry is that MAT can be prescribed as standalone medication without the behavioral therapy that addresses the cognitive and environmental patterns driving use. Medication alone, without counseling, has measurably worse outcomes than medication combined with therapy. This is one of the differentiators of inpatient MAT: the medication is delivered inside a structured program that integrates individual therapy, group therapy, trauma-informed care, family programming, and discharge planning. A patient who completes inpatient MAT and steps down to outpatient continuation with ongoing therapy receives the full evidence-based intervention. A patient who receives a prescription without therapy receives part of it — and part works less well.

A second legitimate concern is premature discontinuation. Patients frequently feel well after several months of MAT and want to stop. Current evidence suggests discontinuation before 12 months produces relapse rates substantially higher than longer-term continuation. The clinical decision to discontinue MAT should be individualized, measured against recovery stability, and made jointly between the patient and an addiction medicine clinician — not driven by external pressure to be "off everything."

Is MAT the Same as Rehab?

No. This question is asked because the terms are often conflated in popular usage, but clinically they describe different things. Rehab is a setting and a program — structured care delivered over days, weeks, or months that combines medical management, behavioral therapy, and social interventions. MAT is a treatment modality — the use of medication as one component of that care. Rehab can include MAT or not. MAT can be delivered inside rehab, in an outpatient clinic, or in an office-based practice. Inpatient rehab that integrates MAT with behavioral therapy is the most complete form of care for moderate-to-severe opioid use disorder. MAT alone without the rest of the program is a narrower intervention that works less well on average.

Does Insurance Cover Inpatient MAT?

Yes. MHPAEA parity rules require commercial plans to cover medically necessary MAT on the same terms as other inpatient medical care. Coverage typically includes the medication, medical administration, and the accompanying behavioral therapy. Extended-release formulations (Sublocade, Vivitrol) frequently require prior authorization, which the facility utilization-review team obtains. Our insurance page details the verification and appeal process.

How to Find Inpatient MAT Programs

The placement line matches patients to in-network residential facilities that integrate MAT. The pre-screen identifies clinical need, preferences around medication choice (agonist vs antagonist), and whether continuation post-discharge should be office-based or depot-injection. Most admissions happen within 24–48 hours of the first call.

Frequently Asked Questions

Why is MAT controversial?

The main criticism is the "trading one drug for another" argument — the concern that replacing heroin or fentanyl with buprenorphine or methadone substitutes one dependency for another. The medical evidence disagrees: buprenorphine and methadone are pharmacologically distinct from misused opioids when dosed correctly, do not produce the intoxication and reinforcement cycle of street opioids, and reduce overdose death by approximately 50% in multiple cohort studies. A legitimate secondary concern is long-term MAT without counseling — medication alone has worse outcomes than medication combined with behavioral therapy, which is why inpatient MAT integrates both.

Is MAT the same as rehab?

No. MAT is a treatment modality — the use of FDA-approved medications to treat opioid use disorder. Rehab is a clinical setting — a structured program of medical, behavioral, and social care. Inpatient rehab typically includes MAT as one component alongside individual therapy, group therapy, medical management, and discharge planning. MAT can also be delivered outside rehab (in an office-based practice, for example), but standalone MAT without behavioral therapy is not equivalent to completing an inpatient program.

How long does MAT treatment last?

MAT duration is clinical, not predetermined. Short-course MAT (30–90 days) is sometimes used during and immediately after inpatient detox to bridge to abstinence. Extended MAT (12 months or longer) is the standard recommendation for most moderate-to-severe opioid use disorder — NIDA and SAMHSA both recommend no fixed upper limit and caution against premature discontinuation. Patients who discontinue MAT before 12 months have substantially higher relapse rates than those who continue beyond one year. The discontinuation decision should be made by the patient and their clinician based on clinical stability, not a calendar.

What is the difference between inpatient and outpatient MAT?

Inpatient MAT is delivered inside a licensed residential treatment program as one component of integrated care — the patient lives at the facility 24/7, receives medication under direct medical supervision, and participates in structured behavioral therapy. Outpatient MAT is delivered in an office-based or program-based setting where the patient lives at home and visits for medication and counseling. Inpatient is the appropriate level of care during active opioid withdrawal, for patients with severe dependence, and when the home environment does not support recovery.

Does insurance cover inpatient MAT?

Yes. Under MHPAEA parity rules, commercial health plans must cover medically necessary MAT on the same terms as other inpatient medical care. Coverage typically includes the medication (buprenorphine, naltrexone, or in rare inpatient cases methadone), the clinical staff time to administer and monitor it, and the associated behavioral therapy. Most plans require prior authorization for extended-release formulations such as Vivitrol or Sublocade, which the admitting facility's utilization-review team handles.